Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AtriCure, Inc.
AtriCure Reports Fourth Quarter and Full Year 2008 Financial Results
March 8th, 2009
AtriCure, Inc.: Highlights 2008 revenues of $55.3 million – up 14% over 2007 2008 minimally invasive product revenues of $19.8 million – up 38% 2008 international revenues of $8.3 million – up 27% 25 patients enrolled to-date in EXCLUDE clinical trial AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, announced revenues for 2008 of $55.3 million and quarterly revenues of $12.1 million for its fourth quarter 2008. The net loss per share for 2008 improved 14.3% to $0.72. “As anticipated, the fourth quarter of 2008 presented several...
Source: Medical Letter on the CDC & FDA (2009-03-08)
|
